Skip to main content

New Weight-Loss Drug Zepbound Is Now Available, Company Says

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 6, 2023.

By Robin Foster HealthDay Reporter

WEDNESDAY, Dec. 6, 2023 -- The newly approved weight-loss medication known as Zepbound is now available for patients to take, drug maker Eli Lilly announced Tuesday.

"Today opens another chapter for adults living with obesity who have been looking for a new treatment option like Zepbound," Rhonda Pacheco, group vice president of Lilly Diabetes and Obesity, U.S., said in a company news release.

"The availability of Zepbound in U.S. pharmacies is the first step, but we have to work hand-in-hand with employers, government and healthcare industry partners to remove barriers and make Zepbound available to those who need it," Pacheco added. "We are excited to see growing [insurance] coverage in the marketplace, giving millions of Americans access to Zepbound."

It was only last month when the U.S. Food and Drug Administration approved Zepbound as a weight-loss medication. Tirzepatide, the active ingredient in Zepbound, had already been approved by the FDA as a treatment for type 2 diabetes called Mounjaro.

To trigger weight loss, tirzepatide mimics two hormones, GLP-1 and GIP, which stimulate the release of insulin in the body. It quells appetite and slows the rate at which food moves through the stomach, helping patients feel full. Novo Nordisk’s weight-loss medication, Wegovy, uses semaglutide, which only focuses on GLP-1.

That difference translated to greater weight loss with Zepbound than Wegovy, a recent study found. Zepbound has been found to prompt up to a 20.9% drop in weight at higher doses, while Wegovy patients typically see a 15% reduction in weight.

According to the FDA, Zepbound’s most common side effects include nausea, vomiting, constipation and diarrhea, according to the FDA.

The drug’s label will also have warnings about the potential for inflammation of the pancreas, gallbladder problems, low blood sugar, acute kidney injury, damage to the retina in people with type 2 diabetes, and suicidal behavior or thinking.

How widely Zepbound will be covered still remains unclear, CNN reported. Medicare and Medicaid can't cover obesity medications, but Lilly said it is offering a savings card for people with private insurance to get Zepbound for $25 for a one- or three-month prescription if their plans cover it. For those whose plans don’t cover Zepbound, the savings card would lower the cost to $550 per month, or roughly half the list price, the company said.

Amid skyrocketing demand for weight-loss drugs, many of these wildly popular drugs have faced supply shortages in recent months.

Sources

  • Eli Lilly, news release, Dec. 5, 2023
  • CNN

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

Read this next

Mediterranean Diet Cuts Women's Risk of Early Death by 23%

FRIDAY, May 31, 2024 -- Experts have long extolled the benefits of the Mediterranean diet and a new study adds to that evidence, finding it cuts the odds for an early death in...

Ozempic Lowers Odds for Death, Illness in People With Kidney Disease and Type 2 Diabetes

FRIDAY, May 24, 2024 -- Ozempic provides a wide variety of health benefits for people with kidney disease and type 2 diabetes, a major clinical trial has found. The drug...

Costs, Side Effects Drive Folks to Quit New Weight-Loss Meds

THURSDAY, May 23, 2024 -- Three months after starting one of the new GLP-1 weight-loss drugs, more than a quarter of patients have already quit the medications, and by a year from...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.